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A number of chemical mediators can induce human
keratinocytes and epidermal-derived carcinomas to un-
dergo apoptosis, or programmed cell death. Recent evi-
dence suggests pro-inflammatory cytokines, such as in-
terleukin-1 or transforming growth factor , protects
carcinomas from numerous pro-apoptotic stimuli. Plate-
let-activating factor (1-alkyl-2-acetyl-3-glycerophospho-
choline; PAF) is a lipid mediator with pro-inflammatory
effects on numerous cell types. Although PAF can be
metabolized to other bioactive lipids, the majority of
PAF effects occur through activation of a G protein-
coupled receptor. Using a model system created by ret-
roviral transduction of the PAF receptor (PAF-R) into
the PAF-R-negative human epidermal cell line KB and
the PAF-R-expressing keratinocyte cell line HaCaT, we
now demonstrate that activation of the epidermal
PAF-R results in protection from apoptosis induced by
tumor necrosis factor (TNF)  or TNF-related apoptosis-
inducing ligand. The PAF-mediated protection was in-
hibited by PAF-R antagonists, and protection did not
occur in PAF-R-negative KB cells. Additionally, we show
protection from TNF- or TRAIL-induced apoptosis by
PAF-R activation is dependent on the transcription fac-
tor nuclear factor (NF)-B, because PAF-R activation-
induced NF-B and epidermal cells transduced with a
super-repressor form of inhibitor B were not protected
by the PAF-R. These studies provide a mechanism
whereby the epidermal PAF-R, and possibly other G
protein-coupled receptors, can exert anti-apoptotic ef-
fects through an NF-B-dependent process.
Apoptosis, or programmed cell death, is a fundamental phys-
iological process enabling the removal of damaged or infected
cells and in the control of cell populations (1). Apoptosis can
occur during embryogenesis, induction, and maintenance of
immune tolerance, development of the nervous system, and
endocrine-dependent tissue atrophy (2). In the skin, apoptosis
is involved in epidermal development and growth and deletion
of UV-damaged keratinocytes (3). In addition to normal phys-
iological conditions, essentially all chemotherapeutic agents
exert their effects by induction of apoptosis (4). Thus, regula-
tion of apoptosis can have important consequences both during
development and in the treatment of cancer.
Recent evidence suggests an association between cancer and
inflammation, with inflammatory mediators affecting the
growth and survival of tumors (5–7). Pro-inflammatory cyto-
kines, such as IL-11 or transforming growth factor , have
been shown to protect human keratinocytes and epidermal-
derived carcinomas against numerous pro-apoptotic stimuli
(8–11). Thus the anti-apoptotic effects exerted by pro-inflam-
matory mediators may provide a mechanism for decreased
effectiveness of chemotherapy. Furthermore, the protective ef-
fect of these cytokines depends upon the de novo synthesis of
protective proteins (10, 11) implicating the activation of epider-
mal transcription factors.
One potential transcription factor that may mediate anti-
apoptotic effects in epithelial cells is NF-B. NF-B proteins
are sequence-specific transcription factors induced in response
to inflammatory and other stressful stimuli (12, 13). Indeed,
exposure to IL-1 or interferon- has been shown to activate
NF-B in primary cultures of human keratinocytes and in
transformed keratinocytes (8, 14). These studies determined
that activation of NF-B mediated the observed anti-apoptotic
activity exerted by IL-1 against TRAIL-induced apoptosis (8).
Coincident to the protection from apoptosis, recent evidence
indicates that activation of epidermal NF-B enhances the
expression of the inhibitor of apoptosis proteins (IAP), such as
c-IAP1 and c-IAP2, which interfere with apoptosis (15, 16).
Expression of IAPs and other anti-apoptotic proteins have been
shown to inhibit apoptosis in various cell types (17–19).
Accumulating evidence suggests platelet-activating factor
(PAF)-mediated pathways are involved in cutaneous inflamma-
tion and keratinocyte stress responses (20). PAF (1-alkyl-2-
acetyl glycerophosphocholine) is a glycerophosphocholine-de-
rived lipid mediator implicated in numerous inflammatory
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processes. Keratinocytes synthesize PAF and related 1-acyl-
PAF-like species in response to various stimuli including iono-
phores, growth factors, PAF agonists, the pro-oxidative stres-
sor, tert-butyl hydroperoxide, ultraviolet light irradiation, or
acute thermal damage (21–24). Although PAF can be metabo-
lized to other biologically active lipids, the majority of PAF
effects appear to be mediated by interaction with a G protein-
coupled receptor (GPCR), the PAF receptor (PAF-R). In addi-
tion to producing PAF, keratinocytes also express the PAF-R
(21), and activation of the epidermal PAF-R leads to the pro-
duction and release of PAF, IL-6, IL-8, TNF, and eicosanoids
(23, 25).
Although the ability of cytokines to protect keratinocytes
from apoptosis has been established, and potential mecha-
nisms for this protection have been suggested, it is unclear
whether PAF has anti-apoptotic effects. However, several lines
of evidence suggest that epidermal PAF may inhibit apoptosis.
First, PAF can be produced under the same conditions that
induce apoptosis and thus may have a role in the regulation of
apoptosis. Exposure to chemotherapeutic agents, such as cis-
platin, gentamycin, or 5-fluorouracil have been shown to in-
duce PAF production (26, 27). Second, activation of the PAF-R
expressed in Chinese hamster ovary cells has been shown to
stimulate NF-B and induce gene expression (28). Thus, acti-
vation of the keratinocyte PAF-R may induce NF-B expression
and protect keratinocytes in a manner similar to cytokines. Of
significance, activation of the PAF-R has been shown to rescue
B lymphocytes from apoptotic stimuli through an unknown
mechanism (29).
Because PAF is produced during inflammation and oxidative
stress and activates signal transduction pathways similar to
the anti-apoptotic effects of growth factors and cytokines, we
sought to determine whether apoptosis in epidermal cells can
be modulated by PAF. In this paper, we report that activation
of the epidermal PAF-R protects from apoptosis induced by
either TNF or TRAIL. This protective effect was inhibited by
pretreatment with PAF-R antagonists. Stimulation of epider-
mal cells with a PAF receptor agonist resulted in a rapid
degradation of IB and subsequent increase in NF-B binding.
Furthermore, the protective effect induced by PAF-R activation
was abolished in epidermal cells expressing a super-repressor
form of IB, indicating that the PAF-R-induced protective ef-
fect was mediated by activation of an NF-B-dependent path-
way. Thus, these results demonstrate that, in addition to the
anti-apoptotic actions induced by growth factors and cytokines,
activation of GPCRs such as PAF-R may also protect epithelial
cells from pro-apoptotic agents.
EXPERIMENTAL PROCEDURES
Reagents—All chemicals were obtained from Sigma unless indicated
otherwise. Recombinant human TRAIL/APO2L was purchased from
Chemicon (Temecula, CA). Recombinant human IL-1 and TNF were
from PeproTech (Rocky Hill, NJ), the broad-spectrum caspase inhibitor
2-Val-Ala-Asp-FMK (2-VAD-FMK) was purchased from Alexis Bio-
chemicals (San Diego, CA). The PAF-R antagonist WEB-2086 was
kindly provided by Boehringer Ingelheim (Ridgefield, CT) and A-85783
was a gift from Dr. James Summers (Abbot Pharmaceuticals, Abbott
Park, IL).
Cell Culture—The human epidermoid cell line KB and human kera-
tinocyte cell line HaCaT cells were grown in Dulbecco’s modified Eagle’s
medium (Life Technologies, Inc.) were supplemented with 10% fetal
bovine serum (Intergen, Purchase, NY). A KB PAF-R model system was
created by transduction of PAF-R-negative KB cells with the MSCV2.1
retrovirus encoding the human leukocyte PAF-R as described previ-
ously (25, 30). KB cells transduced with the PAF-R (KBP) or with
control MSCV2.1 retrovirus (KBM) were characterized by Southern and
Northern blot analysis and by radioligand binding and calcium mobili-
zation studies to demonstrate that the PAF-R was functional (25, 30).
All experiments were replicated with at least two separate KBM and
KBP clones.
Generation of KBP Cells Expressing the Super-repressor IB
(IBM)—The IBM containing S32A and S36A mutation of IB has
previously been described (31), and the retroviral DNA vector MIEG3,
which uses enhanced green fluorescent protein as the selectable
marker, was a kind gift of Dr. David Williams (Indiana University) (32).
To create KBP cells stably expressing IBM, the IBM cDNA was
subcloned into the EcoRI site of MIEG3, and orientation was assessed
by restriction endonuclease mapping and sequencing. Infectious am-
photropic retroviruses were produced from both MIEG-IBM and con-
trol MIEG backbone by transient transfection using standard protocols
(33). Briefly, the Phoenix amphotropic packaging cell line was trans-
fected with the DNA constructs using Fugene-6, and the supernatants
collected 48 h later containing infectious virions were then used to
infect KBP cells. Transduced cells were fluorescence-activated cell sort-
er-sorted on the basis of enhanced green fluorescent protein expression
Immunoblotting—Cells were washed twice with ice-cold phosphate-
buffered saline and lysed with radioimmune precipitation buffer (150
mM NaCl, 50 mM Tris-HCl, pH 8.0, 0.1% SDS, 0.5% sodium deoxy-
cholate, 1% Nonidet P-40) containing 0.5 mM Pefabloc SC (Roche Mo-
lecular Biochemicals) and 10 mM sodium orthovanadate for 20 min on
ice. IB degradation was determined by immunoblotting with poly-
clonal anti-IB antibody (Santa Cruz Biotechnology) and enhanced
chemiluminescence (Amersham Pharmacia Biotech).
Cell Viability Assay—Cells were plated at a density of 1.0  104
cells/well in 96-well plates and allowed to stabilize for 1 day. Cells were
then treated for 24 h with fresh medium containing the indicated
agents. Cell viability was determined using a 3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenyltetrazolium bromide assay (Roche Molecular Biochemi-
cals) and analyzed using a microplate reader (Molecular Devices,
Sunnyvale, CA). The effects of treatment are expressed as a percentage
of viable cells using the untreated cells as the maximum cell viability.
DNA Fragmentation Analysis—Low molecular weight DNA was ex-
tracted from KB cells after TNF or TRAIL treatment at the indicated
times using the Stratagene DNA extraction kit (Stratagene, La Jolla,
CA). 40 g of total genomic DNA was separated on a 2.0% agarose gel,
and the gel was stained with ethidium bromide.
Cell Death Detection Assay—Apoptosis was determined quantita-
tively using a cell death detection enzyme-linked immunosorbent assay
(Roche Molecular Biochemicals) according to the manufacturer’s in-
structions. The kit measures the enrichment of mono- and oligonucleo-
somes released into the cytoplasm of apoptotic cells as a result of DNA
degradation. The absorption was measured at 405 nm using a micro-
plate reader (Molecular Devices, Sunnyvale, CA). The enrichment fac-
tor was calculated using the following formula: absorbance of apoptotic
cells/absorbance of control cells.
Caspase-3 Assay—The activation of the caspase proteolytic cascade
was measured by the direct assay of caspase-3 enzyme activity in cell
lysates using a synthetic fluorogenic substrate (caspase-3 substrate,
Ac-Asp-Glu-Val-Asp-AMC (Ac-DEVD-AMC); Alexis Biochemicals, San
Diego, CA) as described previously (34). Reactions were performed for
1 h at 37 °C. Release of the fluorogenic AMC moiety was measured
using a Hitachi F2000 spectrophotometer (excitation, 380 nm; detec-
tion, 460 nm). The fluorescent intensity was converted to pmol of AMC
released by comparison to standards of AMC (Molecular Probes, Eu-
gene, OR). The specific activity of caspase-3 in cell lysates was deter-
mined following quantitation of the total protein in the cell lysates
(NanoOrange protein quantitation reagent; Molecular Probes, Eugene,
OR).
Electrophoretic Mobility Shift Assay—Whole cell extracts were pre-
pared and subjected to electrophoretic mobility shift assay as described
previously (31). Protein-DNA binding reactions were performed for 30
min at room temperature using 6 g of whole cell extract and 32P-
labeled oligonucleotide probes for NF-B consensus binding sites (Pro-
mega, Madison, WI). Complexes were separated by electrophoresis on
nondenaturing 6% acrylamide gel and assayed by autoradiography.
NF-B Reporter Assay—Cells were plated at a density of 1.5  106
cells in a 10-cm dish and allowed to stabilize for 1 day. Cells were then
transfected using Fugene6 (Roche Molecular Biochemicals) with 10 g
of NF-B-luciferase reporter plasmid (pNF-B-luc) and 10 g of pCMV-
-galactosidase as an internal control for the transfection efficiency.
24 h after transfection, cells were treated with CPAF and IL-1 or were
mock-treated and then harvested in reporter lysis buffer (Promega)
following an additional 6-h incubation. 20-l aliquots of the lysates
were assayed for -galactosidase and luciferase activities using an
LB9501 luminometer (Lumat). Luciferase activities were normalized
for each transfection using the control -galactosidase activities.
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RESULTS
Because PAF may have both receptor-dependent and -inde-
pendent effects (secondary to the formation of biologically ac-
tive metabolites), our laboratory has previously created a
model system by transduction of the PAF-R into a PAF-R-
deficient epidermal cell line to study the role of the PAF-R in
keratinocyte cell biology. The human epidermal cell line KB,
originally obtained from a patient with an oral squamous cell
carcinoma (36), does not express functional PAF-Rs, unlike
normal human keratinocytes and the human keratinocyte-de-
rived cell line HaCaT (21, 22). A PAF-R-positive KB cell line,
KBP, was created by transducing KB cells with a replication-
deficient MSCV2.1 retrovirus containing the human PAF-R
cDNA. KB cells were also transduced with the retrovirus back-
bone alone to establish a vector control cell line, KBM. Expres-
sion of the PAF-R protein was verified by binding studies using
radiolabeled PAF-R antagonist WEB-2086 (25). Calcium mobi-
lization studies demonstrated that the KB PAF-R was func-
tionally active (25, 30). Therefore, this in vitro epidermoid
system consists of both PAF-R-negative (KBM) and -positive
(KBP) cells.
In initial experiments, the dose-response and time-response
of TNF- and TRAIL-induced apoptosis were determined using
activation of caspase-3, a cell death detection enzyme-linked
immunosorbent assay, and DNA fragmentation as three dis-
tinct markers of apoptosis in epidermal cells. Exposing KBP
cells to 100 ng/ml TNF or 40 ng/ml TRAIL for various times
was found to induce caspase-3-specific activity (Fig. 1A), enrich
the release of mono- and oligonucleosomes into the cytoplasm
(Fig. 1B), and enhance DNA fragmentation as shown by DNA
laddering (Fig. 1C). Inasmuch as these markers of apoptosis
determined that TNF and TRAIL treatment resulted in a
maximal apoptotic effect after 24 h, subsequent experiments
therefore examined apoptosis at the 24-h time point. In addi-
tion to KBP cells, treatment with TNF- or TRAIL-induced
apoptosis in KBM and HaCaT cells was similar to that ob-
served in KBP cells (data not shown).
To determine whether PAF-R activation affects TNF family-
mediated apoptosis in epidermal cells, KB cells were pre-
treated with the metabolically stable PAF agonist, CPAF. Pre-
treatment of KBP cells for 1 h with 100 nM CPAF resulted in a
decrease in the TRAIL- and TNF-induced apoptosis (Fig. 2A,
black bars), shown as a decrease in caspase-3-specific activity
and decreased enrichment of nucleosomes in the cytoplasm
(Fig. 2B); however, CPAF had no effect on apoptosis in the
PAF-R-deficient KBM cells (Fig. 2A, gray bars). In contrast to
the actions of CPAF, pre-treating cells for 1 h with 25 ng/ml
IL-1 protected both KBP and KBM cells from TRAIL- and
TNF-induced apoptosis. These results confirm the studies of
Schwartz and co-workers (8, 9) that IL-1 protects KB cells
from TRAIL-induced apoptosis. Furthermore these results sug-
gest that the anti-apoptotic effects of PAF are mediated by
activation of the PAF-R, because CPAF inhibited apoptosis in
KBP, but not KBM, cells.
To further confirm whether the protective effects of CPAF
were mediated through a PAF-R-dependent mechanism, we
determined whether the selective PAF-R antagonists A-85783
(ABT) or WEB2086 (WEB) could block the protective effects of
PAF. As shown in Fig. 3A, exposure to WEB or ABT abolished
the anti-apoptotic effects of PAF. Neither ABT nor WEB had
any direct effect alone on TRAIL-induced apoptosis. In addi-
tion, pre-treatment with WEB or ABT did not affect the anti-
apoptotic effects of IL-1 in KBP cells (Fig. 3B). Taken to-
gether, these results indicate that activation of the PAF-R
mediates the protective effects of PAF on epidermal cells.
To address whether the protective effects induced by CPAF
FIG. 1. Effect of TNF- (black col-
umns) and TRAIL (gray columns) on
apoptosis in KBP cells. KBP cells were
treated with 100 ng/ml TNF- or 40 ng/ml
TRAIL for 0–24 h. Following the treat-
ment duration, the cells were collected
and lysed, and (A) caspase-3-specific ac-
tivity and (B) enrichment of nucleosomes
into the cytoplasm were determined as an
index of apoptotic activity after treat-
ment. C, DNA fragmentation was exam-
ined after 24 h of treatment with TNF or
TRAIL and using UVB as a positive con-
trol (Con).
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were secondary to the overexpression of PAF-R in KBP cells,
we also examined the protective role of physiological levels of
the PAF-R in the immortalized keratinocyte cell line, HaCaT.
Our laboratory has demonstrated previously that HaCaT cells
express functional PAF-Rs (21, 25). As illustrated in Fig. 4,
treatment with 100 nM CPAF or 25 ng/ml IL-1 for 1 h prior to
exposure to TRAIL or TNF protected HaCaT cells from TNF-
and TRAIL-induced apoptosis in a manner similar to the pro-
tective effect observed with KBP cells. Taken together, these
results demonstrate that activation of the PAF-R, a GPCR,
protects keratinocyte and epidermal carcinoma cells from
apoptosis.
To determine whether the PAF-R-mediated protection from
apoptosis would affect the survival of epidermal cells, we ex-
amined the viability of cells treated with either TRAIL or TNF
in the presence or absence of CPAF, IL-1, or the nonspecific
caspase inhibitor z-VAD-fmk. TRAIL and TNF treatment de-
creased the number of viable KBP cells by 41.6  1.8 and
49.5  8.3%, respectively (Fig. 5). Pre-treatment of KBP cells
for 1 h with 100 nM CPAF or 25 ng/ml IL-1 protected cells,
shown as a 25–30% increase in cell viability. Treatment with 10
M of the caspase inhibitor z-VAD-fmk also blocked the de-
crease in cell viability induced by TRAIL and TNF. Thus, the
cytoprotective actions induced by the PAF-R exerted a survival
effect on TRAIL- and TNF-treated epidermal cells, presum-
ably by inhibiting apoptosis.
Because pro-inflammatory cytokines and growth factors can
induce anti-apoptotic effects through activation of the tran-
scription factor NF-B, we next examined whether the PAF-R
protective effects were similarly mediated through an NF-B-
dependent pathway. Exposure to CPAF or IL-1 induced a
time-dependent degradation of IB in KBP cells resulting in
the disappearance of immunoreactive IB within 15–20 min
(Fig. 6A). Secondary to the degradation of IB, NF-B binding
activity was increased and reached maximal activity1 h after
treatment (Fig. 6B). However, CPAF did not induce IB deg-
radation nor increase NF-B binding activity in control KBM
cells unlike IL-1, which induced NF-B in both KBP and KBM
cells (data not shown). To establish that the PAF-R is function-
ally coupled to a pathway leading to activation of NF-B, KBP
cells were transfected with a luciferase reporter containing
NF-B consensus binding sites and were then stimulated with
CPAF or IL-1. Exposure to CPAF or IL-1 resulted in a 6.2 
1.0 (n  6)- or 5.1  0.5 (n  6)-fold increase in NF-B-depend-
ent gene transcription over unstimulated cells, respectively
(Fig. 6C). Thus, activation of the PAF-R is functionally coupled
to a biochemical pathway that results in NF-B activation and
gene transcription.
FIG. 2. Effect of CPAF and IL-1 on TNF-- and TRAIL-induced
apoptosis in KBP (black columns) and KBM (gray columns). The
cells were treated with 100 nm CPAF or 25 ng/ml IL-1 for 1 h prior to
exposure to 100 ng/ml TNF- or 40 ng/ml TRAIL for 24 h. Following the
treatment duration, the cells were collected, lysed, and (A) caspase-3-
specific activity/mg of protein and (B) enrichment of nucleosomes into
the cytoplasm were determined as an index of apoptotic activity in KBP
cells. Data represent the -fold difference in activity or enrichment
compared with untreated control (CON).
FIG. 3. Effect of PAF-R antagonists, WEB or ABT, on the pro-
tective effect of (A) CPAF or (B) IL-1. KBP cells were exposed to 10
m WEB or ABT 30 min prior to pretreatment with CPAF or IL-1.
Following pretreatment, the cells were exposed to 40 ng/ml TRAIL for
24 h. The cells were collected and lysed, and caspase-3-specific activi-
ty/mg of protein was determined as an index of apoptotic activity. Data
represent the -fold difference in activity compared with untreated con-
trol (CON).
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To determine whether the PAF-R protective effects were
dependent on the NF-B pathway, KBP cells were transduced
by retroviral infection to express a super-repressor IB protein
(KBP-MIEG-IBM). Whereas both CPAF and IL-1 induced
IB degradation and increased NF-B binding activity in KBP
cells transfected with the vector backbone (KBP-MIEG), the
stimulated IB degradation (Fig. 7A) and NF-B binding ac-
tivity (Fig. 7B) were abolished in KBP-MIEG-IBM cells. Fur-
thermore, the CPAF- and IL-1-induced protection from TNF-
and TRAIL-induced apoptosis were decreased in KBP-MIEG-
IBM cells (Fig. 7, C and D), indicating that the anti-apoptotic
activity induced by PAF-R is mediated by an NF-B-dependent
pathway. In addition to abolishing the protective effects, treat-
ment with TNF resulted in an augmentation of apoptosis in
KBP-MIEG-IBM cells compared with KBP-MIEG cells; how-
ever, TRAIL-induced apoptosis was similar in KBP-MIEG-
IBM and KBP-MIEG cells. These findings are supported by
previous studies that demonstrated that the inhibition of the
NF-B pathway sensitizes various cells types to TNF-induced
apoptosis (37–39). Taken together, these findings support the
hypothesis that activation of the epidermal PAF-R results in an
NF-B-dependent protection from the pro-apoptotic stimula-
tion induced by TNF and TRAIL.
DISCUSSION
These studies provide evidence that in epidermal cells, the
PAF-R can protect against apoptosis induced by TNF receptor
superfamily members via an NF-B-dependent process. The
protective effect of CPAF, but not IL-1, occurred through
activation of the PAF-R, because the protection from apoptosis
was only seen in PAF-R-expressing KBP and HaCaT cells, and
the protection was inhibited by using PAF-R antagonists. Our
results describe a novel function for a G protein-coupled recep-
tor, namely the induction of an NF-B-dependent, anti-apo-
ptotic pathway by which the PAF-R receptor can protect carci-
nomas from chemotherapy-induced apoptosis and describes a
putative mechanism in tumors for the pro-survival effects as-
sociated with inflammation and inflammatory mediators (5–7).
Several lines of evidence suggest that the PAF-R-induced
protection from apoptosis involves an NF-B-dependant trans-
duction cascade. Activation of the PAF-R in KBP and HaCaT
cells resulted in a rapid, time-dependent degradation of IB
and corresponding increase in NF-B binding activity, which
was not observed in PAF-R-deficient KBM cells (data not
FIG. 4. Effect of CPAF and IL-1 on TNF-- and TRAIL-induced
apoptosis in the human keratinocyte cell line, HaCaT. The cells
were treated with 100 nm CPAF or 25 ng/ml IL-1 for 1 h prior to
exposure to 100 ng/ml TNF- or 40 ng/ml TRAIL for 24 h. Following the
treatment duration, the cells were collected and lysed, and caspase-3-
specific activity/mg of protein was determined as an index of apoptotic
activity. Data represent the -fold difference in activity compared with
untreated control (CON).
FIG. 5. Effect of CPAF, IL-1, or the caspase inhibitor z-VAD-
fmk on viability of KBP cells treated with TNF- or TRAIL. The
cells were treated with 100 nm CPAF, 25 ng/ml IL-1, or 10 m
z-VAD-fmk for 1 h prior to exposure to 100 ng/ml TNF- or 40 ng/ml
TRAIL for 24 h. Following the treatment duration, the cell viability was
determined using a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazo-
lium bromide cell growth/death assay. Data represent the percent of
viable cells compared with untreated control.
FIG. 6. Effect of CPAF and IL-1 on IB degradation and
NF-B binding and activity in KBP cells. A, following the treat-
ment with 100 nm CPAF or 25 ng/ml IL-1, the cells were harvested
and lysed with radioimmune precipitation buffer. Approximately 40 g
of protein was separated on a 10% SDS-polyacrylamide gel electro-
phoreses, and IB immunoreactivity was determined using a poly-
clonal antibody. IB, immunoblot. B, for NF-B binding whole cell ex-
tracts were obtained through three cycles of freeze/thaw and diluted to
a concentration of 2 g/ml in lysis buffer. Whole-cell extracts were
incubated with radiolabeled NF-B probe and electrophoretically sep-
arated. C, KBP cells transfected with NF-B luciferase reporter gene
were stimulated with CPAF or IL-1 for 6 h, and relative luciferase
activity was normalized to -galactosidase.
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shown). The kinetics of PAF-induced NF-B activation in epi-
dermal cells are similar to results with PAF-R transfected into
Chinese hamster ovary cells (28). In addition, both the IB
degradation and increased NF-B binding activity were abol-
ished in KBP cells expressing a super-repressor form of IB.
The inhibition of PAF-stimulated NF-B activation effectively
blocked the PAF-induced protection from apoptosis in KBP
cells. These results confirm the findings of Schwarz and co-
workers (8, 9) that the IL-1-induced protection is mediated by
the NF-B pathway and thus establish that stimulation of the
NF-B pathway either by cytokines or by PAF can protect
against TRAIL-induced apoptosis. Also similar to the results
with IL-1, we found that PAF-mediated protection occurred
when the PAF-R was stimulated prior to or concurrent with
apoptotic stimulation, as the addition of PAF following TRAIL
or TNF treatment did not protect cells from apoptosis. The
time course of protection suggests that activation of NF-B is
necessary prior to induction of apoptosis for any protective
effects. Our results are also supported by observations in other
cell types that activation of NF-B protects from apoptosis
induced by members of the TNF receptor superfamily (39–42).
Taken together, our results establish that in addition to growth
factors and cytokines, G protein-coupled receptor agonists that
activate the NF-B pathway can provide anti-apoptotic effects.
In addition to the present finding that PAF-R activation
protects from apoptosis induced by members of the TNF re-
ceptor superfamily, PAF has also been shown to protect B-
lymphocytes from apoptosis that occurs during immune cell
maturation (29). In a similar manner, growth factors and cy-
tokines such as tumor growth factor  and IL-1 can protect
keratinocytes from TNF- and TRAIL-induced apoptosis (8,
10). Our findings that PAF can exert protective effects from
apoptosis appear to contradict previous studies suggesting that
PAF acts to enhance apoptosis. Indeed PAF has been shown to
augment ionophore-induced apoptosis in T cells (43). Further-
more, studies from our group have demonstrated that PAF can
augment the UV radiation induced-apoptosis in epidermal cells
(44). Thus, the ability of PAF or cytokines to exert protective
effects may be dependent upon the specific type of pro-apoptotic
stimulation. For example, PAF protects keratinocytes from
TNF-induced apoptosis but enhances UV-induced apoptosis
in keratinocytes. In support of this hypothesis, it should be
noted that the protective effects of the PAF-R on TRAIL-in-
duced apoptosis required new RNA and protein synthesis,
whereas the pro-apoptotic effects of the PAF-R following UV
were not affected by RNA and protein synthesis inhibitors (44).
The PAF-R is not unique in this respect as IL-1 had been
shown to protect keratinocytes from Fas- and TRAIL-induced
apoptosis but enhances the apoptotic response to UV (8, 9).
Although our results indicate that activation of the PAF-R
induces anti-apoptotic actions through an NF-B-dependent
pathway, the precise mechanisms of PAF-R-mediated protec-
tion remains unknown. Studies in epidermal cells have sug-
gested that the IAP mediate the IL-1 protective effect from
TRAIL-induced apoptosis (9). IAPs block numerous apoptotic
stimuli, including cell death induced by irradiation, growth
factor withdrawal, and exposure to chemotherapeutic agents
including agents acting on death receptors (45–47) by directly
binding and inhibiting caspase proteins, including caspase-3
(48, 49). Thus, it is interesting to speculate that the PAF-R-
induced protection might be mediated by IAPs in a manner
similar to IL-1. However, protection from apoptosis may re-
FIG. 7. Effect of CPAF and IL-1 on
NF-B induction and PAF-R-medi-
ated anti-apoptotic effects in KBP-
MIEG (control cells) and KBP-MIEG-
IBM (expressing super-repressor
IB) cells. Following treatment with 100
nm CPAF or 25 ng/ml IL-1, cells were
collected, and (A) IB-immunoreactivity
and (B) NF-B binding activity was deter-
mined. C and D, KBP-MIEG (gray col-
umns) and KBP-MIEG-IBM (black col-
umns) cells were treated with CPAF or
IL-1 for 1 h prior to exposure to 100
ng/ml TNF- or 40 ng/ml TRAIL for 24 h.
Following the treatment duration, the
cells were collected and lysed, and (C)
caspase-3-specific activity/mg of protein
or (D) enrichment of nucleosomes into the
cytoplasm was determined as an index of
apoptotic activity. Data represent the
-fold difference in activity or enrichment
compared with untreated control (CON).
IB, immunoblot.
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sult from the induction of proteins other than IAPs or may
involve the actions of multiple anti-apoptotic proteins. Re-
cently, the NF-B-induced expression of Bcl-xL and the TRAIL
decoy receptor DcR1 were reported to protect cells from TRAIL-
induced apoptosis (39, 42, 50). Whereas Bcl-xL family members
can block TRAIL-induced apoptosis by preventing the release
of cytochrome c (51, 52), TRAIL decoy receptors have been
proposed to act as functional antagonists by acting to attenuate
the apoptotic actions of TRAIL (53). PAF has been shown to
enhance the expression of Bcl-xL (54) and thus may modulate
apoptosis through this pathway; however, the expression of
TRAIL decoy receptors on primary keratinocytes has been re-
ported to not affect the sensitivity to TRAIL-induced apoptosis
compared with immortalized keratinocytes (55), suggesting
that the PAF-R protection does not likely result from the pro-
duction of decoy TRAIL receptors. Additional studies are un-
derway in our laboratory to determine the downstream effect(s)
of PAF-R-mediated anti-apoptotic actions.
Recent studies have suggested that chronic inflammatory
conditions are associated with an increased pre-disposition to
cancer (5–7) putatively by enhancing the survival of tumor
cells. Inasmuch as the PAF system appears to play an impor-
tant role in keratinocyte function and stress responses, this
lipid mediator could also be an important cellular survival
agent. Although human keratinocytes and epidermal cell lines
do not synthesize significant amounts of PAF under resting
conditions, numerous diverse stimuli associated with inflam-
mation including reactive oxygen species, cytokines, and phys-
ical damage, in addition to UV radiation and chemotherapy, as
well as PAF-R activation itself, all result in significant levels of
PAF biosynthesis in these cell types. Keratinocytes also ex-
press functional PAF-Rs, and activation of the epidermal
PAF-R leads to the biosynthesis and release of numerous pro-
inflammatory mediators including IL-6, -8, and TNF, as well as
release of PAF (21–23, 25, 30). Thus, the ability of the PAF-R to
activate NF-B and thereby protect epidermal cells from apo-
ptosis appears to provide one putative mechanism for the pro-
inflammatory-mediated decrease in tumor susceptibility to
chemotherapy. Further studies are warranted to determine
whether other GPCRs may be involved in the protection of
cancer cells from apoptosis that occurs during inflammation.
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